针对选择性抑制CLK3激酶的研究
Vinay Kumar Singh1,2, Frédéric Justaud1, Dabbugoddu Brahmaiah3
1Univ Rennes, CNRS, ISCR (Institut des Sciences Chimiques de Rennes), UMR 6226, F-35000 Rennes, France.
Beilstein journal of organic chemistry
|October 29, 2025
概括
科学家们开发了VS-77,这是一个强大的抑制剂,向CLK3激酶,对于mRNA拼接至关重要. 这一发现促进了对CLK3的理解.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 类似cdc2的激酶 (CLKs) 家族在生物过程中起着至关重要的作用,特别是mRNA剪接.
- 由于缺乏选择性抑制剂,CLK3的特定功能仍然不太了解.
- CLKs与各种细胞功能和疾病有关.
研究的目的:
- 为了确定一个选择性抑制剂的CLK3.
- 了解CLK3抑制的结构基础.
- 开发针对CLK家族激酶的新型治疗剂.
主要方法:
- 对CLK异型的结构分析,以识别独特的特征.
- 基于结构的药物设计和药物化学方法.
- 生物化学测试以确定抑制剂功效 (IC50).
主要成果:
- 氨酸241被确定为CLK3中的独特残留物,使得有针对性的抑制剂设计成为可能.
- 从低活性分子DB18中开发出一种衍生物VS-77.
- VS-77对CLK3具有显著的亲和力,其IC50为0.3μM.
- VS-77在整个CLK家族中表现出泛抑制活性.
结论:
- VS-77是一种强大的CLK抑制剂,对CLK3具有特别的亲和力.
- 氨酸241的鉴定为开发同型选择性CLK抑制剂提供了战略.
- VS-77代表了研究CLK家族激酶及其在生物过程中的作用的有前途的新工具.
- 对VS-77的进一步研究可能会为涉及异常mRNA拼接的疾病带来新的治疗策略.
相关概念视频
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Positive Regulator Molecules
6.5K
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
6.5K
M-Cdk Drives Transition Into Mitosis
6.2K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.2K
The JAK-STAT Signaling Pathway
11.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
11.9K
Anaphase Promoting Complex
3.3K
The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
3.3K
Enzyme Inhibition
91.5K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
91.5K


